首页> 外文期刊>Cancer causes and control: CCC >Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data.
【24h】

Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data.

机译:2型糖尿病遗传易感性变异与胰腺癌风险的关联研究:PanScan-I数据分析。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To examine associations between recently identified common type 2 diabetes (T2D) susceptibility genetic variants and pancreatic cancer risk. METHODS: Using data on individuals of European ancestry from the Cancer Genetic Markers of Susceptibility PanScan-I study (1,763 pancreatic cancer cases and 1,802 controls), we tested associations for 37 T2D susceptibility variants with pancreatic cancer risk. Associations with pancreatic cancer were also tested for three composite T2D susceptibility measures, incorporating data on all 37 variants, and for ten additional variants related to T2D-related phenotypes, including fasting glucose and beta-cell function. RESULTS: Of the 37 T2D risk alleles, two showed nominally significant positive associations with pancreatic cancer risk (FTO rs8050136 per-allele OR = 1.12; CI: 1.02-1.23; MTNR1B rs1387153 OR = 1.11; CI: 1.00-1.23) and one showed an inverse association (BCL11A rs243021 OR = 0.88; CI: 0.80-0.97). The composite T2D susceptibility measures were not associated with pancreatic cancer. The glucose-raising allele of MADD rs11039149 was associated with increased risk of pancreatic cancer (OR = 1.14; CI: 1.03-1.27). CONCLUSIONS: Overall, these results do not provide strong evidence that common variants underling T2D or related phenotypes also affect pancreatic cancer risk; however, associations for FTO, MTNR1B, BCL11A, and MADD variants warrant further investigation in larger studies. Hypothesis-driven analyses of existing genome-wide genetic data can be cost-efficient and promising approaches for investigating genetic susceptibility to complex diseases.
机译:目的:探讨最近发现的常见2型糖尿病(T2D)易感性遗传变异与胰腺癌风险之间的关联。方法:使用来自欧洲遗传学个体的数据,来自PanScan-I研究的癌症遗传标记(1,763例胰腺癌病例和1,802例对照),我们测试了37种T2D易感性变异与胰腺癌风险的相关性。还测试了与胰腺癌相关的三项综合性T2D敏感性指标,并纳入了所有37种变异的数据,以及与T2D相关表型有关的十种其他变异,包括空腹血糖和β细胞功能。结果:在37个T2D风险等位基因中,有两个显示出与胰腺癌风险的名义上显着正相关(FTO rs8050136每个等位基因OR = 1.12; CI:1.02-1.23; MTNR1B rs1387153 OR = 1.11; CI:1.00-1.23),其中一个显示反向关联(BCL11A rs243021 OR = 0.88; CI:0.80-0.97)。 T2D敏感性综合指标与胰腺癌无关。 MADD rs11039149的葡萄糖升高等位基因与胰腺癌的风险增加相关(OR = 1.14; CI:1.03-1.27)。结论:总的来说,这些结果没有提供有力的证据表明T2D或相关表型下的常见变异也影响胰腺癌的风险。但是,FTO,MTNR1B,BCL11A和MADD变体的关联值得在更大的研究中进一步研究。由假设驱动的现有全基因组遗传数据分析可能是具有成本效益的方法,并且有望用于调查复杂疾病的遗传易感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号